Latest news
Latigo Biotherapeutics Raises 345 Million Dollars in Nasdaq IPO - sekbernews.idsekbernews.id · Sat, 08 Aug 2026 10:25:39 GMTLatigo Biotherapeutics Prices $345.6 Million IPO - MoomooMoomoo · Fri, 07 Aug 2026 21:59:50 GMTLatigo Biotherapeutics, Clinical-Stage Developer of Selective Nav1.8 Non‑Opioid Pain Medicines for Acute and Chronic Pain, Files for Nasdaq Global Select Market IPO - TradingViewTradingView · Fri, 07 Aug 2026 20:39:00 GMTLatigo, BlossomHill cap busy week in biotech IPOs with nearly $500M haul - FirstWord PHARMAFirstWord PHARMA · Fri, 07 Aug 2026 17:52:10 GMTPain drug developer Latigo rises post-upsized IPO (LTGO:NASDAQ) - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 16:27:44 GMTBlossomHill, Latigo outshine IPO expectations with oversubscribed debuts - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 15:10:10 GMTLatigo Biotherapeutics Ups IPO to 19.2 Million Shares - MoomooMoomoo · Fri, 07 Aug 2026 15:04:39 GMTLatigo raises USD 345.6m in upsized IPO backed by Nav1.8 Phase II data - AllSciAllSci · Fri, 07 Aug 2026 13:30:11 GMT